
|Articles|February 15, 2004
Corneal implant applications expand to include keratoconus
Washington, DC-Micro-thin prescription inserts (Intacs, Addition Technology), which received FDA approval in the United States in 1999 for the treatment of mild myopia, are an alternative to tissue-ablating laser vision procedures and have a number of advantages.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Kodiak Sciences releases follow-up, 20-week data from APEX study
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
From then to next: Five decades of transformation in ophthalmology
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5


















































.png)


